Evidence map›Paper›PMID 33579788›Full record

ArticleGut2021

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

Colleen Gc McGregor, Alex Adams, Ross Sadler, Carolina V Arancibia-Cárcamo, Rebecca Palmer, Tim Ambrose, Oliver Brain, Alissa Walsh, Paul Klenerman, Simon Pl Travis and 3 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Guideline
  2. High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Colleen Gc McGregorTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK colleen.mcgregor@ndm.ox.ac.uk.ORCID 0000-0002-4090-0375
Alex AdamsTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.ORCID 0000-0001-9364-8540
Ross SadlerDepartment of Laboratory Immunology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Carolina V Arancibia-CárcamoTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
Rebecca PalmerTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
Tim AmbroseTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
Oliver BrainTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
Alissa WalshTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
Paul KlenermanTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
Simon Pl TravisTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.ORCID 0000-0002-2690-4361
Nicholas M CroftCentre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-1519-6435
James O LindsayCentre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK.
Jack SatsangiTranslational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
University of Oxford · GBQueen Mary University of London · GBOxford University Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Inflammatory Bowel DiseasesAntibodies, Monoclonal, HumanizedHumansInfliximabPandemicsSARS-CoV-2United KingdomAntibodies, Monoclonal, HumanizedInfliximabvedolizumabCOVID-19inflammatory bowel diseaseinfliximabpaediatric gastroenterology

Identifiers

PMID33579788
OpenAlexW3128496509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.